Review Papers Against Their Own Results

 Quick Explanation Copied

 Long Explanation

Evidence Summary

The paper reports four converging lines of evidence that CBL can function as a degrader E3 In vitro and cellular ubiquitination evidence: (1) fusion of CBLock to eIF4E enables CBL-dependent ubiquitination in vitro at four lysines; (2) SPR confirms ternary complex formation (K_D 42.9–64.6 nM for CBL binding; 38.9–67.5 nM for eIF4E binding), with no detectable cooperativity; (3) cell-penetrating CP-eIFTerminator4 degrades endogenous eIF4E in HeLa and U-2 OS cells in a CBL/CBL-B siRNA-dependent manner, blocked by both carfilzomib and chloroquine; (4) eIF4A1 and eIF4G1 also decrease, with 61.5% translation reduction (SD ±23.2, n=3) and proteome-wide remodeling (1779 down vs 1207 up proteins) Cellular degradation and translation data.

Critical Assessment

Strengths: the mechanistic chain (ternary complex → ubiquitination → dual-pathway degradation → translational collapse) is internally consistent, data are deposited (PRIDE PXD063494/PXD071639, Mendeley), and siRNA epistasis properly establishes CBL/CBL-B dependency. This addresses a real gap: CRBN/VHL PROTACs failed to degrade eIF4E previously, and systematic efforts show most of the 600+ E3s remain untapped PROTACtable E3 universe. Independent proximity assays likewise confirm that E3 choice, not target binding, often gates degradation RiPA E3 pairing assay.

Limitations and blind spots: (i) Dmax of ~39–44% is modest, and the eIF4E-knockout negative control was unavailable, so absolute degradation ceilings are uncertain; (ii) how eIF4A/eIF4G are depleted is explicitly unresolved—the authors themselves flag inability to distinguish direct from indirect proteome effects; (iii) the Ub chain type routing eIF4E to lysosome vs proteasome is unknown; (iv) only peptidic, micromolar-potency PROTACs were tested—small-molecule CBL ligands exist but are unproven here Author-stated limitations; (v) CBL is a tumor-suppressive E3 in myeloid cells—germline CBL loss drives JMML CBL tumor suppressor evidence—so pan-CBL engagement carries oncogenic risk the paper does not discuss; (vi) no in vivo data.

What would change the conclusion: demonstration that degradation persists with CBL/CBL-B reconstitution at endogenous levels, identification of the lysosomal-routing Ub signal, or failure to replicate eIF4E loss with a catalytically dead CBL. Confidence in the core proof-of-concept is high; confidence in therapeutic tractability is low.

 BGPT Paper Review

Study Novelty

First demonstration of CBL as a degrader E3 and first PROTAC-mediated degradation of eIF4E, though it fits the established pattern of expanding the E3 toolbox beyond CRBN/VHL.

Scientific Quality

Rigorous multi-assay validation with deposited data; weakened by modest Dmax, missing eIF4E KO control, low replicate counts (n=2–3), and unresolved mechanism of eIF4A/eIF4G depletion.

Study Generality

Establishes a new E3 platform potentially generalizable to other cytosolic neo-substrates, but only one target (eIF4E) is demonstrated; scope across substrates remains unproven.

Study Usefulness

Provides a fast (30-min) chemical tool to acutely degrade eIF4E and a new E3 handle for undruggable targets; therapeutic relevance limited by peptide delivery and micromolar potency.

Study Reproducibility

Proteomics (PRIDE), raw gels, SPR, and AlphaLISA data deposited; methods detailed; however some key figures rest on only n=2 replicates.

Explanatory Depth